Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series

To evaluate the efficacy of the combination of pembrolizumab and lenvatinib in MMR deficient (dMMR) endometrial cancer (EC) patients who previously failed to respond to single-agent pembrolizumab. A retrospective review of MMR deficient endometrial cancer patients was performed. Patients who failed...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Peter G., Feldman, Myra, Podzielinski, Iwona, Petty, Aaron P., Vargas, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694061/
http://dx.doi.org/10.1016/j.gore.2023.101303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694061/
http://dx.doi.org/10.1016/j.gore.2023.101303

Ejemplares similares